277 related articles for article (PubMed ID: 10543448)
1. Biochemical characterization of the catalytic domain of membrane-type 4 matrix metalloproteinase.
Kolkenbrock H; Essers L; Ulbrich N; Will H
Biol Chem; 1999 Sep; 380(9):1103-8. PubMed ID: 10543448
[TBL] [Abstract][Full Text] [Related]
2. Tissue inhibitor of metalloproteinases-4 inhibits but does not support the activation of gelatinase A via efficient inhibition of membrane type 1-matrix metalloproteinase.
Bigg HF; Morrison CJ; Butler GS; Bogoyevitch MA; Wang Z; Soloway PD; Overall CM
Cancer Res; 2001 May; 61(9):3610-8. PubMed ID: 11325829
[TBL] [Abstract][Full Text] [Related]
3. Analysis of tissue inhibitor of metalloproteinases-2 effect on pro-matrix metalloproteinase-2 activation by membrane-type 1 matrix metalloproteinase using baculovirus/insect-cell expression system.
Jo Y; Yeon J; Kim HJ; Lee ST
Biochem J; 2000 Feb; 345 Pt 3(Pt 3):511-9. PubMed ID: 10642509
[TBL] [Abstract][Full Text] [Related]
4. Crystal structure of the complex formed by the membrane type 1-matrix metalloproteinase with the tissue inhibitor of metalloproteinases-2, the soluble progelatinase A receptor.
Fernandez-Catalan C; Bode W; Huber R; Turk D; Calvete JJ; Lichte A; Tschesche H; Maskos K
EMBO J; 1998 Sep; 17(17):5238-48. PubMed ID: 9724659
[TBL] [Abstract][Full Text] [Related]
5. Sequence motifs of tissue inhibitor of metalloproteinases 2 (TIMP-2) determining progelatinase A (proMMP-2) binding and activation by membrane-type metalloproteinase 1 (MT1-MMP).
Worley JR; Thompkins PB; Lee MH; Hutton M; Soloway P; Edwards DR; Murphy G; Knäuper V
Biochem J; 2003 Jun; 372(Pt 3):799-809. PubMed ID: 12630911
[TBL] [Abstract][Full Text] [Related]
6. Immunological characterization of cell-surface and soluble forms of membrane type 1 matrix metalloproteinase in human breast cancer cells and in fibroblasts.
Li H; Bauzon DE; Xu X; Tschesche H; Cao J; Sang QA
Mol Carcinog; 1998 Jun; 22(2):84-94. PubMed ID: 9655252
[TBL] [Abstract][Full Text] [Related]
7. Molecular cloning of a novel membrane-type matrix metalloproteinase from a human breast carcinoma.
Puente XS; Pendás AM; Llano E; Velasco G; López-Otín C
Cancer Res; 1996 Mar; 56(5):944-9. PubMed ID: 8640782
[TBL] [Abstract][Full Text] [Related]
8. Human MT6-matrix metalloproteinase: identification, progelatinase A activation, and expression in brain tumors.
Velasco G; Cal S; Merlos-Suárez A; Ferrando AA; Alvarez S; Nakano A; Arribas J; López-Otín C
Cancer Res; 2000 Feb; 60(4):877-82. PubMed ID: 10706098
[TBL] [Abstract][Full Text] [Related]
9. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.
Sakata K; Shigemasa K; Nagai N; Ohama K
Int J Oncol; 2000 Oct; 17(4):673-81. PubMed ID: 10995877
[TBL] [Abstract][Full Text] [Related]
10. Matrilysin-2, a new matrix metalloproteinase expressed in human tumors and showing the minimal domain organization required for secretion, latency, and activity.
Uría JA; López-Otín C
Cancer Res; 2000 Sep; 60(17):4745-51. PubMed ID: 10987280
[TBL] [Abstract][Full Text] [Related]
11. Catalytic activities of membrane-type 6 matrix metalloproteinase (MMP25).
English WR; Velasco G; Stracke JO; Knäuper V; Murphy G
FEBS Lett; 2001 Feb; 491(1-2):137-42. PubMed ID: 11226436
[TBL] [Abstract][Full Text] [Related]
12. Homophilic complex formation of MT1-MMP facilitates proMMP-2 activation on the cell surface and promotes tumor cell invasion.
Itoh Y; Takamura A; Ito N; Maru Y; Sato H; Suenaga N; Aoki T; Seiki M
EMBO J; 2001 Sep; 20(17):4782-93. PubMed ID: 11532942
[TBL] [Abstract][Full Text] [Related]
13. Direct activation of pro-matrix metalloproteinase-2 by leukolysin/membrane-type 6 matrix metalloproteinase/matrix metalloproteinase 25 at the asn(109)-Tyr bond.
Nie J; Pei D
Cancer Res; 2003 Oct; 63(20):6758-62. PubMed ID: 14583471
[TBL] [Abstract][Full Text] [Related]
14. Catalytic activities and substrate specificity of the human membrane type 4 matrix metalloproteinase catalytic domain.
Wang Y; Johnson AR; Ye QZ; Dyer RD
J Biol Chem; 1999 Nov; 274(46):33043-9. PubMed ID: 10551873
[TBL] [Abstract][Full Text] [Related]
15. Activation of progelatinase A and progelatinase A/TIMP-2 complex by membrane type 2-matrix metalloproteinase.
Kolkenbrock H; Hecker-Kia A; Orgel D; Ulbrich N; Will H
Biol Chem; 1997 Feb; 378(2):71-6. PubMed ID: 9088534
[TBL] [Abstract][Full Text] [Related]
16. Expression of matrix metalloproteinases and their inhibitors in medulloblastomas and their prognostic relevance.
Ozen O; Krebs B; Hemmerlein B; Pekrun A; Kretzschmar H; Herms J
Clin Cancer Res; 2004 Jul; 10(14):4746-53. PubMed ID: 15269148
[TBL] [Abstract][Full Text] [Related]
17. Plasmin activates pro-matrix metalloproteinase-2 with a membrane-type 1 matrix metalloproteinase-dependent mechanism.
Monea S; Lehti K; Keski-Oja J; Mignatti P
J Cell Physiol; 2002 Aug; 192(2):160-70. PubMed ID: 12115722
[TBL] [Abstract][Full Text] [Related]
18. Leukolysin/MMP25/MT6-MMP: a novel matrix metalloproteinase specifically expressed in the leukocyte lineage.
Pei D
Cell Res; 1999 Dec; 9(4):291-303. PubMed ID: 10628838
[TBL] [Abstract][Full Text] [Related]
19. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression.
Hofmann UB; Westphal JR; Zendman AJ; Becker JC; Ruiter DJ; van Muijen GN
J Pathol; 2000 Jul; 191(3):245-56. PubMed ID: 10878545
[TBL] [Abstract][Full Text] [Related]
20. The soluble catalytic domain of membrane type 1 matrix metalloproteinase cleaves the propeptide of progelatinase A and initiates autoproteolytic activation. Regulation by TIMP-2 and TIMP-3.
Will H; Atkinson SJ; Butler GS; Smith B; Murphy G
J Biol Chem; 1996 Jul; 271(29):17119-23. PubMed ID: 8663332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
